Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

George N. Thalmann(University Hospital of Bern), Leland W.K. Chung(VA Palo Alto Health Care System), Sen Pathak(The University of Texas MD Anderson Cancer Center), E. Edmund Kim(The University of Texas MD Anderson Cancer Center), Andrew C. von Eschenbach(Community Initiatives), Haiyen E. Zhau(Cedars-Sinai Medical Center), Shi Chang(The University of Texas MD Anderson Cancer Center), Vicki L. Hopwood, Ploutarchos Anezinis(The University of Texas MD Anderson Cancer Center)
PubMed
May 15, 1994
Cited by 739

Related Papers

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
American Cancer Society Guidelines for the Early Detection of Cancer
|CA A Cancer Journal for Clinicians|2002|1.6k
American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001--Testing for Early Lung Cancer Detection
|CA A Cancer Journal for Clinicians|2001|831
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798